Screener
Viking Therapeutics VKTX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Numerator: | ||
| Net loss attributable to common stockholders | $(158,325) | $(45,629) |
| Denominator: | ||
| Weighted-average common shares outstanding | 115,598,289 | 112,252,173 |
| Less: Weighted-average shares subject to repurchase | (30,211) | (183,095) |
| Denominator for basic and diluted net loss per share | 115,568,078 | 112,069,078 |
| Net loss per share: | ||
| Basic and diluted | $(1.37) | $(0.41) |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's shares (diluted)?
- Viking Therapeutics (VKTX) reported shares (diluted) of 115.6M in Q1 2026.
- How has Viking Therapeutics's shares (diluted) changed year-over-year?
- Viking Therapeutics's shares (diluted) increased by 3.1% year-over-year, from 112.1M to 115.6M.
- What is the long-term trend for Viking Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Viking Therapeutics's shares (diluted) has grown at a 9.9% compound annual growth rate (CAGR), from 307.9M to 449.2M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Viking Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude